

SANGSTER GORDON  
Form 4  
September 28, 2010

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
SANGSTER GORDON

2. Issuer Name and Ticker or Trading Symbol  
MICRUS ENDOVASCULAR CORP [MEND]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Financial Officer

(Last) (First) (Middle)  
821 FOX LANE  
  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
09/27/2010

SAN JOSE, CA 95131

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D) Price			
Common Stock	09/27/2010		D	5,555 (1)	D (2) 0	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: SANGSTER GORDON - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (Right to Buy)	\$ 17.51	09/27/2010		D	27,156	(3) 11/12/2017	Common Stock	27,156
Stock Option (Right to Buy)	\$ 17.51	09/27/2010		D	22,844	(3) 11/12/2017	Common Stock	22,844
Stock Option (Right to Buy)	\$ 11.42	09/27/2010		D	2,084	(3) 05/14/2018	Common Stock	2,084
Stock Option (Right to Buy)	\$ 9.19	09/27/2010		D	23,063	(3) 05/26/2019	Common Stock	23,063
Stock Option (Right to Buy)	\$ 9.19	09/27/2010		D	11,937	(3) 05/26/2019	Common Stock	11,937
Stock Option (Right to Buy)	\$ 11.42	09/27/2010		D	17,916	(3) 05/14/2018	Common Stock	17,916

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SANGSTER GORDON 821 FOX LANE SAN JOSE, CA 95131			Chief Financial Officer	

## Signatures

/s/ Carolyn M. Bruguera, Attorney-in-Fact for Gordon T.  
Sangster

09/28/2010

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 3,333 shares of common stock were purchased under Micrus Endovascular Corporation's 2005 Employee Stock Purchase Plan as follows:  
1,111 shares on September 30, 2009, 1,111 shares on March 31, 2010 and 1,111 shares on September 23, 2010.
- (2) Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., each share of common stock held by the reporting person was converted into the right to receive \$23.40 in cash, without interest.
- (3) Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., this stock option was converted into the right to receive an amount in cash per share subject to the stock option equal to the excess of the per share merger consideration of \$23.40 over the per share exercise price of such stock option, without interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.